SIRONAX

about us

Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases. Since its founding in 2017, Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation. Sironax is currently conducting early clinical studies with SIR2446 and SIR9900, in addition to ongoing preclinical research.

2017-09

Sironax (Cayman) founded
2018-06

Seed financing
2019-04

First preclinical candidate nominated
2019-09

Series A financing
2019-11

First healthy subject dosed
2020-08

Healthy subject Ph1a completed
2020-12

First Ph1b patient study initiated
2021-08

Second Ph1b study initiated
2021-09

Biologics programs jump-started
2021-12
- First Ph1b patient study completed
- First healthy subject dosed for RIPK1i SIR2446
2022-08

Series B financing

2022-08

Series B financing
2021-12
- First Ph1b patient study completed
- First healthy subject dosed for RIPK1i SIR2446
2021-09

Biologics programs jump-started
2021-08

Second Ph1b study initiated
2020-12

First Ph1b patient study initiated
2020-08

Healthy subject Ph1a completed
2019-11

First healthy subject dosed
2019-09

Series A financing
2019-04

First preclinical candidate nominated
2018-06

Seed financing
2017-09

Sironax (Cayman) founded

Pipeline

RESEARCH AREAS

CAREERS

ABOUT US

INNOVATION

MEDIA

CAREERS